National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

TThe annual increase in the prevalence of type 2 diabetes mellitus emphasizes the relevance of the search for new treatment options, along with necessity for regular review of proven therapeutic solutions. Today, dipeptidyl peptidase-4 inhibitors (DPP-4i, gliptins) are effective and safe hypoglycemi...

Full description

Bibliographic Details
Main Authors:	M. V. Shestakova, G. R. Vagapova, O. K. Vikulova, G. R. Galstyan, T. Yu. Demidova, E. N. Dudinskaya, T. P. Kiseleva, A. M. Mkrtumyan, N. A. Petunina, O. N. Tkacheva, V. V. Fadeev, Y. S. Khalimov, E. A. Shestakova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2023-12-01
Series:	Сахарный диабет
Subjects:	dpp-4 inhibitors type 2 diabetes mellitus gliptins sitagliptin
Online Access:	https://www.dia-endojournals.ru/jour/article/view/13110

Similar Items

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01)

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
by: Sharma A, et al.
Published: (2022-06-01)

Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials
by: Awadhesh Kumar Singh, et al.
Published: (2019-01-01)

Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01)

Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay
by: Pallavi Kishor Vawhal, et al.
Published: (2023-01-01)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
by: Amy L. Wilson, et al.
Published: (2021-01-01)

The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
by: Fausto Chiazza, et al.
Published: (2018-05-01)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
by: Chintan Shah, et al.
Published: (2020-03-01)

DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2022-07-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review
by: Srinivasan Vedantham, et al.
Published: (2018-10-01)

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients
by: Antti Nätynki, et al.
Published: (2022-07-01)

3D-QSAR-based pharmacophore determination and design of novel DPP-4 inhibitors
by: Rogić Sanja, et al.
Published: (2022-01-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
by: Bárbara Torrecillas-Baena, et al.
Published: (2023-07-01)

What the future holds for gliptins
by: Radhika Jindal, et al.
Published: (2012-01-01)

Oat globulin peptides regulate antidiabetic drug targets and glucose transporters in Caco-2 cells
by: Feng Wang, et al.
Published: (2018-03-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
by: Petr Busek, et al.
Published: (2022-04-01)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
by: Ali Someili, et al.
Published: (2019-09-01)

Dally is not essential for Dpp spreading or internalization but for Dpp stability by antagonizing Tkv-mediated Dpp internalization
by: Niklas Simon, et al.
Published: (2024-01-01)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
by: Li Zhang, et al.
Published: (2023-09-01)

Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
by: Güle ÇINAR, et al.
Published: (2022-06-01)

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study
by: Hiroshi Sakura, et al.
Published: (2016-12-01)

ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
by: I. A. Bonda
Published: (2017-07-01)

Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
by: Nina A. Petunina, et al.
Published: (2016-12-01)

Hypoglycemic agents and potential anti-inflammatory activity
by: Kothari V, et al.
Published: (2016-04-01)

Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice
by: Wenjuan Liu, et al.
Published: (2017-06-01)

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
by: Naoto Katakami, et al.
Published: (2018-02-01)

Dpp from the anterior stripe of cells is crucial for the growth of the Drosophila wing disc
by: Shinya Matsuda, et al.
Published: (2017-07-01)

Diketopyrrolopyrrole (DPP)-Based Materials and Its Applications: A Review
by: Wei Wei Bao, et al.
Published: (2020-09-01)